Carsoncity Headlines

End Stage Renal Disease Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

 Breaking News
  • No posts were found

End Stage Renal Disease Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

March 26
15:20 2020
End Stage Renal Disease Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

End Stage Renal Disease Market Insight
DelveInsight’s “End Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the End Stage Renal Disease , historical and forecasted epidemiology as well as the End Stage Renal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on End Stage Renal Disease Market Insights, Epidemiology and Market Forecast-2030  

DelveInsight’s “End Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the End Stage Renal Disease , historical and forecasted epidemiology as well as the End Stage Renal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 The End Stage Renal Disease market report provides current treatment practices, emerging drugs, End Stage Renal Disease market share of the individual therapies, current and forecasted End Stage Renal Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current End Stage Renal Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 Key benefits of the report

1. End Stage Renal Disease market report covers a descriptive overview and comprehensive insight of the End Stage Renal Disease epidemiology and End Stage Renal Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. End Stage Renal Disease market report provides insights on the current and emerging therapies.
3. End Stage Renal Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. End Stage Renal Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the End Stage Renal Disease market.

Request for sample pages here -> https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market

End stage renal disease (ESRD), is the last stage of chronic kidney disease. There is no treatment, but many people live long lives while on dialysis (hemodialysis or peritoneal dialysis) or after having a kidney transplant. Both conditions benefit from drug therapy using angiotensin-converting enzyme inhibitors (ACE inhibitors/ACEi) or angiotensin receptor blockers (ARBs). ACEi/ARB therapy not only reduces proteinuria (and albuminuria) but decreases the yearly number of diabetic patients going on to require dialysis. Reduced hyper-filtration is consistent with the clinical observation, and the introduction of ACEi/ARB therapy is associated with an acute decrease in estimated glomerular filtration rate (eGFR) and the fact that more significant eGFR reductions were associated with less long-term loss of renal function. Although ACEi/ARB therapy slows renal functional loss in DN, it by no means induces remission or even halts progression to ESRD. Attempts to achieve improved renal protection recently have focused on further inhibition of the renin-angiotensin system; however, using combinations of ACEi plus ARB or renin blockade plus ACEi or ARB have been disappointing.

Drugs covered
1. Intravenous Triferic
2. AB002
And many others

The key players in End Stage Renal Disease market are:
1. Rockwell Medical Technologies
2. Aronora
And many others

Table of contents

1. Report Introduction
2. End Stage Renal Disease Market Share at a glance
3. End-Stage Renal Disease Background and Overview
4. End-Stage Renal Disease Epidemiology and Patient Population
5. Country Wise End-Stage Renal Disease Epidemiology
5.1. United States
5.2. EU5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Current Treatment & Medical Practices
7. End-Stage Renal Disease Treatments & Medical Practices
8. Current Unmet Needs of End Stage Renal Disease
9. End-Stage Renal Disease Emerging Supportive Therapeutics
10. Key Cross Competition
10.1. Intravenous Triferic: Rockwell Medical Technologies
10.2. AB002: Aronora
11. End-Stage Renal Disease Market Size
11.1. Total 7MM End Stage Renal Disease market analysis (2017–2030)
11.2. Region-Wise End-Stage Renal Disease Market size
11.3. United States
11.4. EU-5
11.4.1. Germany
11.4.2. France
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.5. Japan
12. Market Drivers
13. Market Barriers
14. Appendix
15. End-Stage Renal Disease Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

Request for sample pages here -> https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market

Related Reports:

End-Stage Renal Disease (ESRD) – Epidemiology Forecast to 2030

DelveInsight’s End-Stage Renal Disease (ESRD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of End-Stage Renal Disease (ESRD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/